Streetbeat News

Earnings

ESAB

Analysts have mixed views on ESAB (NYSE:ESAB), with recent ratings showing a range from bullish to indifferent. The average 12-month price target for ESAB has increased to $108.17, up 12.68% from $96.00. Key financial indicators suggest ESAB faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages. ESAB, a leader in welding equipment, was spun off from Colfax in 2022 and generated $2.8 billion in revenue in 2023.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:01 pm

GPOR

Gulfport Energy (NYSE:GPOR) received mixed analyst ratings in the last quarter, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for GPOR is $158.67, indicating a bullish outlook. Despite a significant revenue decline of -51.81% as of December 31, 2023, Gulfport Energy boasts a high net margin of 80.84% and strong financial health indicators such as ROE of 10.27% and ROA of 6.64%. The company's debt-to-equity ratio of 0.32 suggests a sound financial structure.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:00 pm

SMAR

15 analysts have updated their ratings on Smartsheet (NYSE:SMAR), showing a mix of sentiments from bullish to bearish. The average 12-month price target has been lowered to $48.4, a decrease of 11.76%. Analysts have adjusted their ratings and price targets, reflecting a negative shift in sentiment towards Smartsheet. Despite this, Smartsheet has shown a revenue growth rate of 23.22% as of October 31, 2023, but faces challenges in profitability and efficiency metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:00 pm

CSGP

Analysts have provided mixed evaluations of CoStar Gr (NASDAQ:CSGP) with 9 ratings over the last three months, showing a shift towards more bullish perspectives. The average 12-month price target for CSGP has increased to $94.33, with recent actions including both raises and lowers in ratings and price targets by notable analysts. CoStar Group, a leading provider of commercial real estate data, has shown strong financial performance with significant revenue growth, high net margin, and efficient use of equity and assets, alongside prudent debt management.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:00 pm

AMZN

CRWD

GOOG

META

MSFT

NVDA

ORCL

PANW

QOWZ

TRFK

Nvidia's GTC 2024 event, termed the 'AI Woodstock', is anticipated to showcase groundbreaking AI innovations, driving significant analyst enthusiasm. Wedbush analyst Daniel Ives predicts the event will catalyze over $1 trillion in AI investments over the next decade, marking a pivotal moment in the AI Revolution. The introduction of the Blackwell B100 AI chip is highlighted as a key milestone. Major tech companies like Microsoft, Alphabet, Amazon, Oracle, and Meta are noted for their transformative AI investments. The AI sector's growth is expected to significantly impact IT budgets and spur additional spending across software, IT services, and infrastructure. The article also mentions the positive outlook for cloud cybersecurity firms like Zscaler, CrowdStrike, and Palo Alto Networks due to increased AI adoption. Analysts from Truist Securities and HSBC have raised their price targets for Nvidia, reflecting a bullish sentiment on the stock.

Portfolio Pulse from Anusuya Lahiri

March 18, 2024 | 4:56 pm

CBSTF

GTBIF

MRMD

TCNNF

TRSSF

The 4th quarter 2023 earnings for the cannabis sector showed a positive trend with a significant correlation between EBITDA surprises and stock performance. Green Thumb and Trulieve reported notable EBITDA beats, while Marimed, Cannabist, and TerrAscend faced significant misses. Analysts have adjusted their 2024 EBITDA estimates slightly downwards, reflecting modest expectations for revenue growth and margin expansion. The Viridian Cannabis Deal Tracker highlights the importance of these trends for investors.

Portfolio Pulse from Viridian Capital Advisors

March 18, 2024 | 4:46 pm

U.S. Steel (NYSE:X) forecasts Q1 EPS of $0.80-$0.84, below the consensus of $0.89, with adjusted EBITDA around $425 million. The company expects improvements in its Flat-Rolled and Mini Mill segments, while anticipating a decline in the Tubular segment. The merger with Nippon Steel is highlighted as a strategic move towards becoming the 'Best Steelmaker'. Last quarter, U.S. Steel exceeded earnings expectations, and its shares saw a slight increase.

Portfolio Pulse from Lekha Gupta

March 18, 2024 | 4:40 pm

GCT

GigaCloud Technology Inc (NASDAQ:GCT) shares are trading lower today, following a pullback after a surge on Friday due to better-than-expected fourth-quarter earnings. The company reported a Q4 revenue of $244.74 million and earnings of 87 cents per share, surpassing estimates. Marketplace GMV, active third-party sellers, active buyers, and spend per active buyer all saw significant increases. CEO Larry Wu highlighted the quarter as a historic revenue peak and a step forward in global expansion, partly due to the integration of Noble House and Wondersign. GigaCloud has provided a Q1 revenue guidance of $230 million to $240 million, above estimates.

Portfolio Pulse from Adam Eckert

March 18, 2024 | 4:22 pm

GOEV

SOND

SWIN

VERB

WKSP

WLDS

U.S. stocks traded higher with the Dow, NASDAQ, and S&P 500 all seeing gains. The NAHB/Wells Fargo Housing Market Index rose to 51 in March, indicating a positive outlook for the housing market. Canoo Inc. (GOEV) surged 53% after its Oklahoma City facility was approved as a Foreign Trade Zone. Wearable Devices Ltd. (WLDS) and Verb Technology Company, Inc. (VERB) also saw significant gains. Conversely, Solowin Holdings (SWIN), Sonder Holdings Inc. (SOND), and Worksport Ltd. (WKSP) experienced notable declines.

Portfolio Pulse from Avi Kapoor

March 18, 2024 | 4:20 pm

GSK

GSK plc (NYSE:GSK) announced positive Phase 3 trial results for Jemperli in treating primary advanced or recurrent endometrial cancer, showing significant improvements in overall survival and progression-free survival. These results may support FDA approval for expanded use. Jemperli, in combination with other drugs, demonstrated a notable reduction in the risk of death and improvement in survival rates, indicating strong growth potential for GSK's oncology segment.

Portfolio Pulse from Vandana Singh

March 18, 2024 | 4:17 pm